March 18, 2022
Life value
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
THROUGH THE MPP ORGANIZATION, STELLAPHARM GETS THE APPROVAL TO PRODUCE PFIZER’S ANTI-COVID-19 PILL
On February 21, 2022, Stellapharm officially signed a contract with MPP (Medicines Patent Pool), a UNITED NATIONS-backed public health organization to become the only manufacturer in Vietnam allowed to produce a generic version of Pfizer’s oral COVID-19 treatment, nirmatrelvir, which will be co-packaged with ritonavir, under the voluntary licensing agreement between Pfizer and the MPP.
You May like
18
Feb 2022
DRUG ADMINISTRATION GRANTS LICENCES FOR FIRST THREE MADE-IN-VIỆT NAM MOLNUPIRAVIR PRODUCTS
HÀ NỘI — The Drug Administration of Việt Nam under the Ministry of Health has issued the list of three COVID-19 treatment drugs produced in Việt Nam that contain the antiviral ingredient Molnupiravir, which have been granted certificates of registration for conditional use. The three products – Molravir 400mg produced by Boston Việt Nam Pharma (based in
21
Jan 2022
27 GENERIC MANUFACTURERS SIGN AGREEMENTS WITH MPP TO PRODUCE LOW-COST VERSIONS OF COVID-19 ANTIVIRAL MEDICATION MOLNUPIRAVIR FOR SUPPLY IN 105 LOW- AND-MIDDLE-INCOME COUNTRIES
20 January 2022 Geneva – The Medicines Patent Pool (MPP) announced today that it has signed agreements with 27 generic manufacturing companies for the manufacturing of the oral COVID-19 antiviral medication molnupiravir and supply in 105 low- and-middle-income countries (LMICs). The sublicence agreements are the result of the voluntary licensing agreement signed by MPP and